Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

AbbVie and Calico extend collaboration with $1 billion

by Ryan Cross
July 31, 2021 | A version of this story appeared in Volume 99, Issue 28

 

AbbVie and Calico Life Sciences—a biotech firm focused on age-related diseases and funded by Alphabet, Google’s parent company—will extend their research partnership a second time. The two firms, which began collaborating in 2014, have advanced three immuno-oncology and neurodegeneration programs to clinical trials. More than 20 early-stage programs are in the works. Each firm will commit an additional $500 million to the effort, and Calico will helm research and early development until 2025.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.